Thymic peptides for treatment of cancer patients

Wolf, E.; Milazzo, Stefania; Boehm, Katja; Zwahlen, Marcel; Horneber, Markus

doi:10.1002/14651858.cd003993.pub3

Cited by 28 publications

(26 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the most recent methodical review of Wolf and colleagues [110], these parameters were extensively analyzed among other thymic peptides also for T 1. According to the aforementioned clinical studies, T 1 doses up to 6.4 mg were safe, did not induce toxicity and lacked severe side eVects.…”

Section: A-thymosins In Cancer Therapymentioning

confidence: 99%

Prothymosin alpha: a ubiquitous polypeptide with potential use in cancer diagnosis and therapy

Ioannou

Samara

Livaniou

et al. 2012

Cancer Immunol Immunother

View full text Add to dashboard Cite

The thymus is a central lymphoid organ with crucial role in generating T cells and maintaining homeostasis of the immune system. More than 30 peptides, initially referred to as "thymic hormones," are produced by this gland. Although the majority of them have not been proven to be thymus-specific, thymic peptides comprise an effective group of regulators, mediating important immune functions. Thymosin fraction five (TFV) was the first thymic extract shown to stimulate lymphocyte proliferation and differentiation. Subsequent fractionation of TFV led to the isolation and characterization of a series of immunoactive peptides/polypeptides, members of the thymosin family. Extensive research on prothymosin α (proTα) and thymosin α1 (Tα1) showed that they are of clinical significance and potential medical use. They may serve as molecular markers for cancer prognosis and/or as therapeutic agents for treating immunodeficiencies, autoimmune diseases and malignancies. Although the molecular mechanisms underlying their effect are yet not fully elucidated, proTα and Tα1 could be considered as candidates for cancer immunotherapy. In this review, we will focus in principle on the eventual clinical utility of proTα, both as a tumor biomarker and in triggering anticancer immune responses. Considering the experience acquired via the use of Tα1 to treat cancer patients, we will also discuss potential approaches for the future introduction of proTα into the clinical setting.

show abstract

Section: A-thymosins In Cancer Therapymentioning

confidence: 99%

Prothymosin alpha: a ubiquitous polypeptide with potential use in cancer diagnosis and therapy

Ioannou

Samara

Livaniou

et al. 2012

Cancer Immunol Immunother

View full text Add to dashboard Cite

show abstract

“…Peptides of the thymus regulate activity and induce differentiation of T-lymphocytes, thus may contribute to the host defense against cancer. Studies have reported that thymus extracts reduce the risk of infectious complications in patients undergoing cancer treatment and also might have beneficial effects on survival rate [3,5].…”

Section: Discussionmentioning

confidence: 99%

Management of Metastatic Colorectal Carcinoma with GcMAF Forte and Thymus Peptides: A Case Report

Klokol¹,

Teppone²

2016

J Clin Cell Immunol

View full text Add to dashboard Cite

In the recent years immunotherapy has gained important role in cancer management. Immunostimulating effects of thymus-derived peptides on carcinogenesis have been actively studied in both animals and humans. Gc protein derived macrophage-activating factor (GcMAF) was found to have potent effect on macrophage phagocytic activity. Immunostimulating effects of GcMAF and peptides of thymus can be effectively combined together and with other treatment modalities of cancer. The current case report demonstrates outcomes of combination of GcMAF Forte and HT Thymus (peptides of thymus) in the management of metastatic colorectal adenocarcinoma. This case study suggests that individually prescribed immunotherapy can be a promising alternative in management of advance forms of cancer, especially when options of treatment are limited.

show abstract

“…A number of previous review articles [71][72][73][74][75][76][77][78][79][80] address the history, biological effects, and potential therapeutic indications for Ta1.…”

Section: Direct-acting Effectsmentioning

confidence: 99%

Thymosin Apha 1–A Peptide Immune Modulator with a Broad Range of Clinical Applications

King¹

2013

Clin Exp Pharmacol

View full text Add to dashboard Cite

show abstract

Thymic peptides for treatment of cancer patients

Cited by 28 publications

References 38 publications

Prothymosin alpha: a ubiquitous polypeptide with potential use in cancer diagnosis and therapy

Prothymosin alpha: a ubiquitous polypeptide with potential use in cancer diagnosis and therapy

Management of Metastatic Colorectal Carcinoma with GcMAF Forte and Thymus Peptides: A Case Report

Thymosin Apha 1–A Peptide Immune Modulator with a Broad Range of Clinical Applications

Contact Info

Product

Resources

About